Get Started Free
Home›Healthcare›Johnson & Johnson
Johnson & Johnson logo
Johnson & Johnson
Healthcare

Johnson & Johnson Company Overview

Johnson & Johnson logo

Johnson & Johnson

● Active
Healthcare · New Brunswick, New Jersey, USA · Est. 1886
PharmaceuticalsMedTechHealthcareBiotechnology↗ Website
$380.0B
Valuation
$92.0B
Revenue
130k+
Employees
1886
Founded

Johnson & Johnson is one of the world's largest healthcare companies, operating across two segments — Innovative Medicine, which develops and markets prescription pharmaceuticals for oncology, immunology, neuroscience, and cardiovascular diseases, and MedTech, which produces surgical robotics, orthopedics, cardiovascular devices, and vision care products. After spinning off its consumer health division as Kenvue in 2023, J&J focuses exclusively on innovative medicine and medical technology.

Recent Press
5 items
Press Release·2026-01-22
J&J Reports Full-Year 2025 Sales of $94.2B, Projects $100B+ for 2026
Johnson & Johnson reported $94.2 billion in 2025 full-year sales and projected 2026 revenues between $100 billion and $101 billion, driven by oncology, neuroscience, and MedTech growth.
Acquisition·2025-12-29
J&J Acquires Halda Therapeutics for $3.05B to Advance Cancer Treatment
Johnson & Johnson completed its $3.05 billion acquisition of Halda Therapeutics on December 29, 2025, gaining the RIPTAC cancer-targeting platform and HLD-0915, a clinical-stage oral therapy for prostate cancer.
Product Launch·2025-10-10
J&J Submits OTTAVA Robotic Surgical System to FDA
Johnson & Johnson submitted its OTTAVA robotic surgical system for FDA clearance in 2025, marking a major step in the company's MedTech division's push into the $7 billion surgical robotics market.
Product Launch·2025-08-15
FDA Approves RYBREVANT FASPRO Plus LAZCLUZE for Lung Cancer
The FDA approved Johnson & Johnson's RYBREVANT FASPRO combined with LAZCLUZE as a first-line treatment for EGFR-mutated non-small cell lung cancer, offering a chemo-free oral combination option.
Press Release·2025-04-30
Johnson & Johnson Receives FDA Approval for IMAAVY (nipocalimab-aahu) for Generalized Myasthenia Gravis
The FDA approved J&J's IMAAVY, a new FcRn blocker, for long-lasting disease control in the broadest population of adults and adolescents with generalized myasthenia gravis who are AChR or MuSK antibody positive.
Company History
10 milestones
Robert Wood Johnson I, his brothers James and Edward founded Johnson & Johnson in New Brunswick, New Jersey in 1886. The company initially produced ready-to-use surgical dressings and antiseptic supplies, building on Joseph Lister's antiseptic methods to address the high rate of post-surgical infections in hospital settings.

Johnson & Johnson Organization Structure & Team

Org Chart
130,000 employees · Click a leader to explore their team
134,000 across 12 departments
Chief Executive Officer
Joaquin Duato
Joseph Wolk — Departments
· 134000 people across 12 depts

Johnson & Johnson Financials, Revenue & Market Share

Annual Revenue
$92.0B
+4% vs prior year
YoY Growth
+4%
From $93.8B to $92.0B
Revenue / Employee
$683K
Annual revenue per full-time employee
Revenue Growth
2021
2022
2023
2024
2025
$93.8B
$79.0B
$85.2B
$88.8B
$92.0B
Market Share
Global Pharmaceutical (Oncology and Immunology)
6%
share
Johnson & Johnson
6%
Pfizer
7%
Roche
7%
AbbVie
5%
Novartis
5%
$2.8T
TAM
$600.0B
SAM
$88.8B
SOM
Revenue Streams
Innovative Medicine (Pharmaceuticals)56%
MedTech (Medical Devices)44%
Business Units
Innovative Medicine56%
J&J's pharmaceutical segment encompassing oncology (Darzalex, Erleada, Balversa), immunology (Tremfya, Stelara), neuroscience (Spravato, Concerta), and cardiovascular drugs — generating $49.3B in 2024 revenues and targeted at growing J&J's oncology and immunology leadership despite Stelara's patent cliff.
MedTech44%
J&J's medical device segment covering surgery (Ottava robotic platform, Ethicon wound closure), orthopedics (DePuy Synthes joints, CERAMENT), cardiovascular (Shockwave IVL, Abiomed Impella), and vision (ACUVUE contact lenses) — generating $39.6B in 2024 revenues with the cardiovascular platform as the primary growth driver.

Johnson & Johnson Internal Tools & Processes

Internal Tools
12 departments
Innovative Medicine — Oncology12000 people · 3 roles
Standards & Certifications
10 standards
Compliance frameworks, security audits, and quality certifications this company maintains.
Quality
FDA 21 CFR Part 820 (QSR)
Certified
Johnson & Johnson MedTech's manufacturing facilities comply with FDA 21 CFR Part 820 Quality System Regulations, ensuring that medical devices including DePuy Synthes orthopedic implants, Ethicon surgical instruments, and Shockwave IVL systems are manufactured, tested, and documented according to FDA good manufacturing practice requirements.
Quality
ISO 13485
Certified
J&J MedTech holds ISO 13485 medical device quality management system certification across its global manufacturing network, providing an internationally recognized framework for the design, development, and production of surgical robots (Ottava), cardiovascular devices (Impella), and orthopedic implants (DePuy Synthes) sold in 100+ countries.
Quality
GMP (21 CFR Parts 210/211)
Certified
Johnson & Johnson's Innovative Medicine manufacturing facilities comply with FDA Current Good Manufacturing Practice regulations for pharmaceutical production, ensuring that oncology drugs (Darzalex, Erleada), immunology biologics (Tremfya, Stelara), and CNS treatments (Spravato) are manufactured with validated processes and stringent quality controls.
Quality
ICH Q10 Pharmaceutical Quality System
Compliant
J&J Innovative Medicine's global pharmaceutical operations comply with ICH Q10 guidelines for pharmaceutical quality system management, integrating risk management, knowledge management, and continual improvement processes across its active pharmaceutical ingredient and finished drug product manufacturing operations for biologics and small molecule drugs.
Regulatory
EU MDR (2017/745)
Compliant
J&J MedTech has completed the EU Medical Device Regulation (MDR 2017/745) conformity assessment process for its core device portfolio — including DePuy Synthes implants, Ethicon surgical stapling systems, and Shockwave IVL catheters — maintaining CE marking under the stricter post-market surveillance and clinical evidence requirements of the EU MDR framework.
Privacy
HIPAA
Compliant
Johnson & Johnson's US pharmaceutical and medical device operations comply with HIPAA Privacy and Security Rules governing the handling of protected health information collected through patient support programs, Janssen CarePath hub services, and clinical trial data systems supporting J&J's Innovative Medicine drug commercialization activities.
Environmental
ISO 14001 Environmental Management
Certified
Johnson & Johnson maintains ISO 14001 environmental management system certification across its global manufacturing operations, supporting J&J's commitment to achieve carbon neutrality by 2030 and net-zero carbon across its value chain by 2045 — including pharmaceutical manufacturing facilities and MedTech device production plants worldwide.
Security
SOC 2 Type II
Certified
J&J's digital health platforms — including Janssen CarePath patient support portals, MedTech device connectivity platforms, and clinical trial data management systems — maintain SOC 2 Type II certification for security, availability, and confidentiality controls governing patient health data processed through J&J's healthcare technology infrastructure.
Regulatory
FCPA Compliance Program
Compliant
Johnson & Johnson maintains a comprehensive Foreign Corrupt Practices Act compliance program governing its global pharmaceutical and medical device commercial operations in 150+ countries, including anti-bribery training for sales and marketing staff, third-party due diligence for distributors and healthcare professional interactions, and DOJ/SEC compliance monitoring requirements.
Safety
IEC 62304 Medical Device Software
Compliant
J&J MedTech's software-embedded medical devices — including Ottava surgical robotics, Impella heart pump controllers, and Shockwave IVL console software — comply with IEC 62304 medical device software lifecycle process standards, ensuring safety-classified software is designed, tested, and maintained according to FDA and international regulatory requirements for safety-critical medical software.

Johnson & Johnson Interview Preparation

Interview Prep
Role-specific interview questions and keywords. Select a department, then click any role to prepare.
Innovative Medicine — Oncology· 3 roles

Johnson & Johnson Products & Competitors

Product Suite
5 products · select one to explore
Healthcare
Hardware
Ottava Robotic Surgical System
Intelligent surgical assistance. Designed for the OR of the future.

Ottava is J&J MedTech's next-generation robotic surgical platform designed to assist surgeons across soft-tissue procedures including general surgery, gynecology, and urology. Built with a fully integrated boom-mounted design that maximizes OR floor space, Ottava uses AI-assisted visualization and instrument control to enhance surgical precision.

Use Cases
Performing a laparoscopic cholecystectomy using Ottava's robotic arm assistance and 3D visualization for a general surgery residentIntegrating Ottava with the hospital's OR scheduling and instrument tracking systems for case turnover optimizationCredentialing a surgical team on Ottava using J&J MedTech's simulation-based training curriculum
No image
Key Customers
VUMC
Vanderbilt University Medical Center
HCA
HCA Healthcare
ASC
Ascension Health
Competitive Intelligence
VSda Vinci (Intuitive Surgical)
THEM

The da Vinci Surgical System is Intuitive Surgical's robotic platform with over 10,000 installed units globally, offering multiport and single-port configurations for soft-tissue minimally invasive surgery across urology, gynecology, and thoracic procedures.

EDGE

Boom-mounted design eliminates cart footprint, freeing OR floor space versus da Vinci's floor-based system

VSHugo RAS (Medtronic)
THEM

Hugo is Medtronic's robotic-assisted surgery system with a modular arm design approved for urological and gynecological procedures, offering competitive placement in robotic surgery to challenge Intuitive Surgical's dominance.

EDGE

AI-assisted visualization and deeper integration with J&J's Ethicon surgical energy and stapling portfolio

VSVersius (CMR Surgical)
THEM

Versius is CMR Surgical's portable robotic system designed for minimal access surgery with a smaller footprint, targeting hospitals in Europe and emerging markets where OR space is constrained.

EDGE

Backed by J&J MedTech's global installation, training, and service infrastructure

Related Companies

Eli Lilly logo
Eli Lilly
Healthcare
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets medicines across diabetes, oncology, immunology, and neuroscience. Its GLP-1 receptor agonist portfolio — Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity — drove record revenue growth and positioned Lilly as one of the world's most valuable pharmaceutical companies.
Agilent Technologies logo
Agilent Technologies
Healthcare
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical analysis, providing instruments, software, services, and consumables for laboratories worldwide. Its customers include pharmaceutical companies, academic research institutions, environmental labs, and food safety organizations that rely on Agilent's measurement science for analysis, testing, and compliance workflows.
Abbott Laboratories logo
Abbott Laboratories
Healthcare
Abbott Laboratories is a global healthcare company that develops and manufactures medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Its portfolio spans the FreeStyle Libre continuous glucose monitoring system — the world's most-used CGM — alongside cardiac devices, point-of-care diagnostics, and infant nutrition brands across 160 countries.
Thermo Fisher Scientific logo
Thermo Fisher Scientific
Healthcare
Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services for scientific research, bioprocessing, clinical diagnostics, and pharmaceutical manufacturing. With over $44B in annual revenue, Thermo Fisher serves pharmaceutical and biotech companies, academic research institutions, clinical laboratories, and government agencies with an unmatched portfolio spanning mass spectrometry, chromatography, cell culture, genetic analysis, and laboratory equipment.
Medtronic logo
Medtronic
Healthcare
Medtronic is the world's largest standalone medical device company, developing therapies and diagnostics across cardiac rhythm management, surgical robotics, neuromodulation, diabetes technology, and endoscopy. Its portfolio spans implantable cardiac monitors, transcatheter pacemakers, robotic surgery platforms, and closed-loop insulin delivery systems used in over 150 countries.
Stryker Corporation logo
Stryker Corporation
Healthcare
Stryker is one of the world's leading medical technology companies, offering a broad portfolio of innovative products and services in orthopedics, medical and surgical equipment, and neurotechnology. The company serves surgeons, hospitals, and healthcare systems across 75 countries with products ranging from joint replacement implants and surgical robots to emergency medical equipment.